Atai Life Sciences rises on mid-stage data for alcohol use disorder therapy

AtaiBeckley

28/01/2025 12:52

** U.S. shares of drug developer Atai Life Sciences  9VC.DE 
 ATAI.O  rise 5.5% to $1.53 premarket
    ** Co, along with partner Beckley Psytech, reports results
from mid-stage trial of its experimental treatment for alcohol
use disorder
    ** Co says a single dose of the therapy, BPL-003, in
combination with behavioral therapy shows sustained reduction in
alcohol use and heavy drinking days up to 12 weeks
    ** The study enrolled 12 patients with the disorder -
characterized by an impaired ability to stop or control alcohol
use despite adverse health consequences
    ** BPL-003 was shown to be well-tolerated with no serious or
severe adverse events reported
    ** Co anticipates reporting additional data from this study
in publications and conferences later this year
    ** ATAI fell 5.6% in 2024

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))